Skip to main content
. 2026 Jul 13;17:1893876. doi: 10.3389/fendo.2026.1893876

Figure 2.

Panel A displays a schematic of experimental design comparing a control group and an STZ-induced diabetic renal injury mouse model with timelines for sampling and intervention, including Adropin and saline treatments. Panel B is a line graph showing fasting blood glucose (FBG) increasing in the STZ group over eight weeks, while remaining steady in controls. Panel C is a line graph depicting elevated twenty-four-hour urinary protein (UP) in the STZ group versus controls over eight weeks. Panel D is a line graph illustrating decreasing serum Adropin in the STZ group, while remaining stable in controls. Panels E–H are bar graphs showing that Adropin treatment significantly reduces FBG (E), twenty-four-hour UP (F), serum creatinine (SCr, G), and blood urea nitrogen (BUN, H) compared with the diabetic kidney disease group, with statistical significance indicated by asterisks.

Effects of adropin intervention in an STZ-induced mouse model of diabetic kidney disease. (A) Schematic overview of the experimental design. (B–D) Fasting blood glucose (FBG), 24-h urinary protein excretion, and serum adropin levels measured at 8 weeks after DKD induction (prior to intervention). (E–H) FBG, 24-h urinary protein excretion, serum creatinine (Scr), and blood urea nitrogen (BUN) measured after 4 weeks of treatment in DKD mice receiving adropin or vehicle. ****p < 0.0001. One-way ANOVA was used for multiple comparisons.